DEFA14A: Masimo Defends Performance and Strategy Amidst Politan's Proxy Fight

Masimo refutes Politan Capital's claims, asserting strong healthcare business performance and a credible plan for future growth, while urging shareholders to vote for Masimo's nominees.

Summary

• Masimo has issued a press release addressing what it believes are misrepresentations made by Politan Capital regarding the company's performance and strategic direction.
• The company defends its proposed consumer joint venture, stating it will not compete with Masimo's healthcare business and CEO Joe Kiani will only support it with unanimous board approval.
• Masimo asserts its directors are truly independent, unlike Politan's nominees who have ties to Quentin Koffey.
• The company highlights its strong healthcare business performance, with average annual revenue growth of 12% since 2007 and adjusted EBIT margins increasing from ~19% in 2017 to ~24% in 2024.
• Masimo claims to have a credible plan to achieve 30% EBIT margins and $8 earnings per share by 2029.
• The company denies engaging in empty voting and encourages stockholders to vote for Masimo's nominees.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as Masimo defends its performance and strategy, but the ongoing proxy fight introduces uncertainty.

Positives

• Masimo's healthcare business has shown strong revenue growth and margin improvement.
• The company has a clear plan to achieve higher profitability by 2029.
• Masimo's management is actively defending the company's strategy and performance against activist challenges.
• Masimo's professional healthcare EBIT margins (~24%) are higher than most peers today (> 75th percentile), with a path to 30% EBIT margins clearly in view (> 98th percentile).

Negatives

• Masimo is facing a proxy fight with Politan Capital, indicating shareholder dissatisfaction.
• The company experienced gross margin headwinds due to inflationary costs and currency headwinds.
• The proposed consumer joint venture has caused mistrust among shareholders.

Risks

• Uncertainties surrounding the potential separation of Masimo's consumer business.
• Potential actions by Politan in furtherance of its director nominations.
• The cost and management distraction associated with the proxy contest.
• The company acknowledges risks related to uncertainties regarding future actions that may be taken by Politan.

Future Outlook

Masimo aims to achieve 30% EBIT margins and $8 earnings per share by 2029. The company is shifting manufacturing to Malaysia to reach goals of 70% gross margins and 30% EBIT margins.

Management Comments

• Masimo CEO Joe Kiani has committed that he will not support the proposed joint venture unless the entire Board, including Mr. Koffey, also supports it.
• Mr. Kiani is the largest individual shareholder of Masimo and would not do anything to harm the Company.

Industry Context

The document highlights Masimo's position relative to its peers, noting that its professional healthcare EBIT margins are higher than most and that it is aiming for even higher margins that would place it in the top percentile. The company also claims that other companies have tried to emulate it.

Comparison to Industry Standards

• Masimo's professional healthcare EBIT margins (~24%) are higher than most peers today (> 75th percentile).
• Masimo aims to achieve 30% EBIT margins, which would place it in the > 98th percentile compared to its peers.
• Masimo's SG&A expenses are already lower than 70% of industry peers.
• Masimo already plans to reduce its R&D expenses from 9% to 8%, which is in line with industry peers.

Stakeholder Impact

• The outcome of the proxy fight and the proposed joint venture could significantly impact shareholder value.
• The company's performance and strategic decisions affect employees, customers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote FOR Joe Kiani and Christopher Chavez using the GOLD proxy card.
• The company is awaiting the outcome of the 2024 Annual Meeting of Stockholders.

Key Dates

Keywords

Masimo, Politan Capital, proxy fight, joint venture, healthcare, EBIT margins, revenue growth, board of directors, Joe Kiani, Quentin Koffey